Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The problem of polypharmacy in heart failure.

Markus Flesch1, Erland Erdmann

  • 1Klinik III für Innere Medizin, der Universität zu Köln, Kerpener Strassxe 62, 50937 Köln, Germany.

Current Cardiology Reports
|June 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoadsorption in dilated cardiomyopathy: the IASO-DCM trial.

European heart journal·2026
Same author

Multicentre, randomized, double-blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO-DCM): Rationale and design.

European journal of heart failure·2024
Same author

Prevalence and predictors of sleep-disordered breathing in chronic heart failure: the SchlaHF-XT registry.

ESC heart failure·2022
Same author

ECG as a risk stratification tool in patients with wearable cardioverter-defibrillator.

Journal of cardiology·2022
Same author

Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE-HF major sub study.

Journal of sleep research·2022
Same author

Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series.

International journal of molecular sciences·2022
Same journal

Diagnostic Tests for Stage B Heart Failure.

Current cardiology reports·2026
Same journal

Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.

Current cardiology reports·2026
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
See all related articles

Heart failure patients take more drugs due to improved treatment and multiple conditions. This polypharmacy increases risks like drug interactions, necessitating careful medication selection.

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Medical therapy advances have decreased heart failure morbidity and mortality.
  • Heart failure patients often require multiple medications for comorbidities and age-related conditions.
  • This leads to polypharmacy, posing challenges in chronic heart failure management.

Purpose of the Study:

  • To review data on polypharmacy challenges in heart failure.
  • To provide guidance for selecting appropriate heart failure medications.
  • To minimize patient risk associated with complex drug regimens.

Main Methods:

  • Review of existing data on polypharmacy in heart failure.
  • Analysis of drug interactions and patient compliance issues.
  • Evaluation of economic burden and risk mitigation strategies.

Related Experiment Videos

Main Results:

  • Polypharmacy is a significant issue in chronic heart failure care.
  • Unpredictable drug interactions and patient compliance are key concerns.
  • Careful drug selection is crucial for managing heart failure patients.

Conclusions:

  • Optimizing pharmacotherapy is essential for heart failure patients.
  • Minimizing polypharmacy and managing drug interactions can improve outcomes.
  • Guidance on drug selection aids in reducing patient risk.